ストックスクリーナーアプリを入手
60.90
5.61%
3.1991
前日終値:
$57.70
開ける：
$58.11
24時間の取引高:
561.41K
Relative Volume:
0.76
時価総額：
$2.90B
収益：
-
当期純損益:
$-86.97M
株価収益率:
-25.18
EPS:
-2.4189
ネットキャッシュフロー:
$-81.88M
1週間 パフォーマンス:
+10.39%
1か月 パフォーマンス:
+101.24%
6か月 パフォーマンス:
+87.20%
1年 パフォーマンス:
+373.10%
1日の値動き範囲:
$56.17
$61.17
1週間の範囲:
$55.05
$61.17
52週間の値動き範囲:
$9.63
$61.17
Mbx Biosciences Inc Stock (MBX) Company Profile
Compare MBX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
60.91 | 2.75B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
522.41 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.94 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.98 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.29 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.97 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2025-12-04 | 開始されました | Goldman | Sell |
| 2025-11-04 | 開始されました | TD Cowen | Buy |
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-08-15 | 再開されました | Jefferies | Buy |
| 2025-08-05 | 開始されました | Mizuho | Outperform |
| 2025-07-16 | 開始されました | Oppenheimer | Outperform |
| 2025-04-10 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | JP Morgan | Overweight |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Stifel | Buy |
すべてを表示
Mbx Biosciences Inc (MBX) 最新ニュース
MBX Biosciences on Track for Record High Close -- Data Talk - Moomoo
MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy) - Seeking Alpha
Price to earnings forward of MBX Biosciences, Inc. – NASDAQ:MBX - TradingView
MBXMBX Biosciences Inc Options - Finviz
Paradigm Biocapital Advisors LP Acquires Significant Stake in MB - GuruFocus
MBX Biosciences Soars on Breakthrough Trial Momentum - TipRanks
Mbx biosciences stock hits all-time high of 54.98 USD - Investing.com
Mbx biosciences stock hits all-time high of 54.98 USD By Investing.com - Investing.com India
MBX Biosciences, Inc.(NasdaqGS:MBX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
MBX Biosciences, Inc.(NasdaqGS: MBX) dropped from Russell 2000 Value Benchmark - marketscreener.com
MBX Biosciences, Inc.(NasdaqGS:MBX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
MBX Biosciences, Inc.(NasdaqGS: MBX) added to Russell 2000 Growth Benchmark - marketscreener.com
Does MBX (MBX) Joining Russell Growth Indexes Mark a Lasting Shift in Its Market Narrative? - simplywall.st
MBX Biosciences, Inc.(NasdaqGS: MBX) added to Russell 3000E Growth Benchmark - marketscreener.com
MBX Biosciences, Inc.(NasdaqGS: MBX) dropped from Russell 3000 Value Benchmark - marketscreener.com
MBX Biosciences, Inc. Actuals & Estimates (NASDAQ:MBX) - TradingView
MBX Biosciences Rises After Positive Clinical Trial Update - TipRanks
MBX Forecast — Price Target — Prediction for 2027 - TradingView
MBX Biosciences Inc (MBX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Paradigm entities disclose multi-million share stakes in MBX (MBX) - Stock Titan
MBX Biosciences highlights sustained calcium control in rare disease - MSN
MBX Biosciences Soars on Breakthrough Trial Results - TipRanks
Mbx Biosciences stock hits all-time high at 45.88 USD By Investing.com - Investing.com Australia
Mbx Biosciences stock hits all-time high at 45.88 USD - Investing.com
MBX Biosciences shares fall despite positive one-year trial results for Canvuparatide (MBX) - MSN
MBX Biosciences Inc (MBX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MBX Biosciences Inc (MBX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MBX Biosciences Inc (MBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Analyst Reiterates Buy on MBX, Maintains $91 Price Target on Canvuparade’s Once-Weekly Hypoparathyroidism Opportunity - TipRanks
MBX Biosciences Inc (MBX) Valuation: PE, PB & Fair Value Analysis - TradingKey
MBX Biosciences Inc (MBX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MBX Biosciences Inc (MBX) Institutional Confidence - TradingKey
MBX Biosciences Inc (MBX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MBX Biosciences Inc (MBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MBX News | MBX BIOSCIENCES INC (NASDAQ:MBX) - ChartMill
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and Alnylam Pharma (ALNY) - The Globe and Mail
MBX updates data from mid-stage trial for endocrine disease therapy - MSN
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Pfizer (PFE) and MBX Biosciences, Inc. (MBX) - The Globe and Mail
How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy? - Yahoo! Finance Canada
Guggenheim Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $88 - Moomoo
Barclays Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $70 - Moomoo
MBX's Flagship Drug Trial Met Expectations But Perhaps Some Investors Wanted More -- Market Talk - Moomoo
MBX Biosciences (MBX) Slips 4.67% as Stock Tests Key Support LevelsHagopian Line - dars.gov.et
Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Health Care Roundup: Market Talk - Moomoo
LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $91 - Moomoo
MBX Biosciences, Inc. Common Stock (NASDAQ: MBX) Share Price, MBX Stock News, MBX Share Price & Updates - Kalkine
Mbx Biosciences90% of Patients in Ole Rema - Moomoo
Street canvu MBX phase II HP data more than one way - BioWorld News
MBX: Once-weekly kanvuparatide maintained durable efficacy and safety at one year, supporting phase III plans - TradingView
MBX reports one-year data for hypoparathyroidism drug candidate - Investing.com UK
Mbx Biosciences Inc (MBX) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
3.14%
大文字化:
|
ボリューム (24 時間):